Get the Stockscreener App
135.83
2.26%
3.00
After Hours:
135.83
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Ligand Pharmaceuticals Inc stock is traded at $135.83, with a volume of 124.87K.
It is up +2.26% in the last 24 hours and up +17.38% over the past month.
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
See More
Previous Close:
$132.83
Open:
$133.62
24h Volume:
124.87K
Relative Volume:
0.89
Market Cap:
$2.62B
Revenue:
$152.42M
Net Income/Loss:
$45.24M
P/E Ratio:
54.12
EPS:
2.51
Net Cash Flow:
$6.97M
1W Performance:
-2.35%
1M Performance:
+17.38%
6M Performance:
+18.08%
1Y Performance:
+28.13%
1-Day Range:
$132.59
$135.83
1-Week Range:
$131.75
$143.13
52-Week Range:
$90.29
$143.13
Ligand Pharmaceuticals Inc Stock (LGND) Company Profile
Name
Ligand Pharmaceuticals Inc
Sector
Industry
Phone
858-550-7500
Address
3911 SORRENTO VALLEY BLVD, SAN DIEGO, CA
Compare LGND with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LGND
Ligand Pharmaceuticals Inc
|
135.83 | 2.56B | 152.42M | 45.24M | 6.97M | 2.51 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Ligand Pharmaceuticals Inc Stock (LGND) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-25 | Initiated | Stifel | Buy |
| Oct-03-24 | Initiated | Oppenheimer | Outperform |
| Jul-30-24 | Initiated | RBC Capital Mkts | Outperform |
| Apr-14-21 | Resumed | Stephens | Overweight |
| Feb-04-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-06-20 | Initiated | Barclays | Overweight |
| Mar-24-20 | Downgrade | Argus | Buy → Hold |
| Mar-10-20 | Initiated | Guggenheim | Neutral |
| Feb-06-20 | Initiated | The Benchmark Company | Buy |
| Sep-19-19 | Upgrade | Barclays | Equal Weight → Overweight |
| Jun-11-19 | Initiated | Barclays | Equal Weight |
| May-03-19 | Reiterated | H.C. Wainwright | Buy |
| Mar-06-19 | Reiterated | H.C. Wainwright | Buy |
| Oct-29-18 | Upgrade | ROTH Capital | Neutral → Buy |
| Oct-02-18 | Reiterated | H.C. Wainwright | Buy |
| Sep-11-18 | Reiterated | Argus | Buy |
| Aug-17-18 | Initiated | Goldman | Neutral |
| Aug-08-18 | Downgrade | ROTH Capital | Buy → Neutral |
| Jun-21-18 | Initiated | Argus | Buy |
| Dec-27-17 | Reiterated | H.C. Wainwright | Buy |
| Sep-05-17 | Resumed | H.C. Wainwright | Buy |
| Oct-05-16 | Reiterated | H.C. Wainwright | Buy |
| Aug-05-16 | Downgrade | Deutsche Bank | Hold → Sell |
| Mar-11-16 | Initiated | Sidoti | Buy |
| Mar-03-16 | Initiated | H.C. Wainwright | Buy |
View All
Ligand Pharmaceuticals Inc Stock (LGND) Latest News
Is Ligand Pharmaceuticals Incorporated stock a growth or value playInvestor Friendly Risk Reward - Metal.it
Ligand Pharmaceuticals Incorporated Stock Analysis and ForecastHigh-margin investment plays - PrintWeekIndia
What drives Ligand Pharmaceuticals Incorporated stock priceBreakout portfolio performance - Autocar Professional
Mark Your Calendar: Ligand Q2 2025 Earnings Report Coming August 7Key Details Inside - Stock Titan
What analysts say about Ligand Pharmaceuticals Incorporated stockExceptional trading performance - Autocar Professional
Is Ligand Pharmaceuticals Incorporated a good long term investmentHigh-velocity capital appreciation - jammulinksnews.com
Analysts Offer Insights on Healthcare Companies: Ligand Pharma (LGND) and Sarepta Therapeutics (SRPT) - The Globe and Mail
Stifel reiterates Buy rating on Ligand Pharma stock at $143 price target - Investing.com Canada
Teacher Retirement System of Texas Has $534,000 Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Ligand Pharmaceuticals stock hits 52-week high at 130.0 USD - Investing.com Australia
Ligand Pharmaceuticals stock hits 52-week high at 130.0 USD By Investing.com - Investing.com Nigeria
What makes Ligand Pharmaceuticals Incorporated stock price move sharplyHigh Yield Opportunities - Newser
How Ligand Pharmaceuticals Incorporated stock performs during market volatilityFree Real-Time Trading Opportunities - Newser
Why Ligand Pharmaceuticals Incorporated stock attracts strong analyst attentionFree Access to Community - Newser
Craig-Hallum Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Announces Target Price $140 - 富途牛牛
Principal Financial Group Inc. Acquires 3,284 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Insider Sell Alert: John Kozarich Sells Shares of Ligand Pharmac - GuruFocus
Ligand Pharmaceuticals director Kozarich sells $116k in stock By Investing.com - Investing.com South Africa
Ligand Pharmaceuticals director Kozarich sells $116k in stock - Investing.com Australia
Ligand Pharmaceuticals Director John Kozarich Sells 934 Shares at $125/Share. - AInvest
Amalgamated Bank Has $564,000 Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Ligand earns $5 million milestone as partner launches molluscum treatment By Investing.com - Investing.com South Africa
Ligand Pharmaceuticals (LGND) Soars 2.11% on ZELSUVMI Launch, Milestone Payment - AInvest
Pelthos Therapeutics shares rise 1.27% in after-hours after commercial launch of ZELSUVMI™ and merger with Channel Therapeutics. - AInvest
Pelthos, Ligand Gain After Launch Of First Prescription-At-Home Treatment For Water Warts - Stocktwits
ZELSUVMI's FDA Approval: A Breakthrough for Pelthos and a Windfall for Ligand? - AInvest
ZELSUVMI Launch Positions Ligand Pharmaceuticals for Growth in a Booming Skin Care Market - AInvest
Ligand earns $5 million milestone as partner launches molluscum treatment - Investing.com
Ligand Partner Pelthos Therapeutics Launches ZELSUVMI - MarketScreener
Ligand Pharmaceuticals Partner Pelthos Launches Molluscum Contagiosum Treatment Zelsuvmi - MarketScreener
Ligand (LGND) Advances with Successful Launch of ZELSUVMI Gel | - GuruFocus
Ligand Pharmaceuticals Partner Pelthos Therapeutics Launches ZELSUVMI™ for Molluscum Contagiosum Treatment - Quiver Quantitative
Ligand Partner Pelthos Therapeutics Launches ZELSUVMI™ - GlobeNewswire
Breakthrough: First-Ever At-Home Treatment for Molluscum LaunchesLigand Secures $5M Milestone Payment - Stock Titan
GAMMA Investing LLC Has $62,000 Stock Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Receives Average Recommendation of “Buy” from Analysts - Defense World
Ligand’s LNHC concludes merger with CHRO - Yahoo Finance
Ligand Pharma Completes Merger Forming Pelthos Therapeutics - TipRanks
Ligand Announces Completion of Pelthos Therapeutics Merger with Channel Therapeutics - The Manila Times
Ligand Pharmaceuticals Inc Stock (LGND) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.97%
0.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):